The transcription factor RORγt regulates differentiation of the T H 17 subset of helper T cells, thymic T cell development and lymph-node genesis. Although elimination of RORγt prevents T H 17 cell-mediated experimental autoimmune encephalomyelitis (EAE), it also disrupts thymocyte development, which could lead to lethal thymic lymphoma. Here we identified a two-aminoacid substitution in RORγt (RORγt M ) that 'preferentially' disrupted T H 17 differentiation but not thymocyte development. Mice expressing RORγt M were resistant to EAE associated with defective T H 17 differentiation but maintained normal thymocyte development and normal lymph-node genesis, except for Peyer's patches. RORγt M showed less ubiquitination at Lys69 that was selectively required for T H 17 differentiation but not T cell development. This study will inform the development of treatments that selectively target T H 17 cell-mediated autoimmunity but do not affect thymocyte development or induce lymphoma.
The transcription factor RORγt (encoded by Rorc2; called 'Rorγt' here) 'instructs' differentiation the T H 17 subset of helper T cells. The activation of naive T cells in the presence of the cytokines TGF-β and IL-6 is sufficient to upregulate their RORγt expression and induce their differentiation into T H 17 cells 1 . T H 17 cells produce the effector cytokines, including IL-17, that mediate the pathological inflammation responsible for autoimmunity, such as psoriasis and multiple sclerosis [2] [3] [4] . In addition, during thymocyte development, RORγt expression is upregulated at the CD4 + CD8 + double-positive (DP) stage to enhance the survival of the thymocytes through upregulation of expression of anti-apoptotic molecule Bcl-x L (ref. 5) . Rorγt −/− mice develop lethal thymic lymphomas that probably result from abnormal thymocyte development 6 . Rorγt −/− mice also lack all lymph nodes, including gut-associated mesenteric lymph nodes and Peyer's patches 5, 7 , due to the requirement for RORγt in the development of lymphoid-tissue-inducer cells, the progenitor cells in lymphnode genesis 5, 8, 9 . The mechanisms that distinguish the functions of RORγt in T H 17 differentiation in the peripheral immune system and its functions thymocyte development in the central immune system remain unknown. Delineating these functions is critical for understanding how one central transcription factor regulates distinct differentiation processes in the peripheral immune system and central immune system. Given the essential function of RORγt in T H 17 cells, inhibitors of RORγt have been developed for the treatment of T H 17 cell-dependent autoimmunity [10] [11] [12] [13] [14] . Such inhibitors are also expected to interfere with the function of RORγt in thymocytes and thus impair T cell development, which could eventually lead to the development of lymphoma 6 . The development of novel RORγt-based treatments that specifically target T H 17 cell-mediated autoimmunity is therefore important 6 .
RORγt is a steroid nuclear receptor that consists of three domains 15, 16 : a conserved DNA-binding domain with two zinc-finger motifs responsible for DNA binding; a conserved ligand-binding domain with a carboxy-terminal AF2 motif responsible for recruiting the SRC family of steroid-receptor transcriptional co-activators to stimulate gene expression 17, 18 ; and a hinge domain between the DNAbinding domain and ligand-binding domain. After binding a ligand, RORγt recruits SRCs and binds to target DNA to regulate target gene expression. So far, no function has been assigned to the RORγt hinge domain, which is generally believed to serve as a flexible linker region between the conserved and functionally important DNA-binding domain and ligand-binding domain. However, the observation that the hinge domain is not conserved among three members of the ROR family 19 suggests a potentially unique function.
By mutagenesis, we identified a mutant form of RORγt with two amino-acid substitutions in its non-conserved hinge region (replacement of the serine at position 92 and leucine at position 93 with alanine (S92A-L93A); called 'RORγt M ' here) that specifically disrupted the function of RORγt in T H 17 differentiation but not in thymocyte development. Mice homozygous for expression of RORγt M from the endogenous Rorγt locus (called 'Rorγt M/M ' here) lacked T H 17 differentiation but had normal overall T cell development and developed most lymph nodes, including gut-associated mesenteric lymph nodes, but lacked Peyer's patches. The alterations in RORγt M interfered with its ubiquitination at Lys69. As with RORγt M , another RORγt mutant with replacement of the lysine at position 69 with arginine (K69R) to prevent its ubiquitination selectively impaired RORγt-mediated T H 17 differentiation but not thymocyte development. Our study thus distinguishes between the function of RORγt in T H 17 differentiation and its function in thymocyte development and reveals distinct mechanisms for these two RORγt-regulated processes.
RESULTS

RORgt supports T cell development and T H 17 differentiation
We established an assay for in vitro thymocyte development and an assay for in vitro T H 17 differentiation to evaluate the distinct functions of RORγt in these two processes. For the former in vitro differentiation system, we cultured sorted CD4 − CD8 − doublenegative (DN) thymocytes from wild-type and Rorγt −/− mice on OP9-DL4 stromal cells to induce differentiation 20 . Wild-type thymocytes differentiated into CD4 + CD8 + DP thymocytes and CD4 + single-positive thymocytes, but Rorγt −/− DN thymocytes did not ( Fig. 1a) . Both wild-type DN thymocytes and Rorγt −/− DN thymocytes lacked RORγt expression, but DP thymocytes that differentiated from wild-type DN thymocytes expressed RORγt (Fig. 1b) . Consistent with published observations 5, 7, 18 , RORγt was upregulated in DP thymocytes and was required for their survival (Fig.  1b) . A population of TCR lo CD24 hi CD8 + thymocytes developed from both wild-type DN thymocytes and Rorγt −/− DN thymocytes ( Supplementary Fig. 1a ) before the DP stage 21 . Thus, we used the frequency of CD4 + cells, including both CD4 + CD8 + DP cells and mature CD4 + single-positive cells, to evaluate the efficiency of thymocyte development (Fig. 1a) . To assess the role of RORγt in thymocyte development, we transduced Rorγt −/− DN thymocytes with retrovirus expressing RORγt and green fluorescent protein (RORγt-GFP) or with empty virus expressing GFP alone (EV-GFP), as a control. Thymocyte development was restored only among RORγt-GFP + cells, not among EV-GFP + cells ( Fig. 1c) or among GFP − cells, which were not transduced by virus ( Supplementary Fig. 1b A r t i c l e s was not restored by the expression of mutant RORγt unable to bind target DNA or mutant RORγt unable to bind SRC co-activators ( Fig. 1c) , although both mutants were expressed at levels equivalent to the expression of wild-type RORγt ( Supplementary  Fig. 1c) , consistent with the proposal that DNA-binding activity and AF2-mediated recruitment of SRCs were required for RORγt to support thymocyte development 18 .
To establish the in vitro T H 17-differentiation assay, we isolated splenic CD4 + T cells from wild-type or Rorγt −/− mice and cultured the cells in T H 17-priming conditions. Rorγt −/− CD4 + T cells, but not wild-type CD4 + T cells, were defective in T H 17 differentiation ( Fig. 1d ) and lacked RORγt expression ( Supplementary Fig. 1d ). The T H 17 differentiation of Rorγt −/− T cells was restored for retrovirustransduced RORγt-GFP + cells but not for retrovirus-transduced EV-GFP + cells ( Fig. 1e ) or GFP − (non-transduced) cells ( Supplementary   Fig. 1e ). Similar to RORγt-mediated T cell development, retroviral expression of mutant RORγt unable to bind target DNA or mutant RORγt unable to bind SRCs, at the same level as the expression of RORγt-GFP ( Supplementary Fig. 1f ), failed to restore T H 17 differentiation ( Fig. 1e ). Therefore, both T cell development and T H 17 differentiation depended on the DNA-binding activity of RORγt and its AF2-mediated recruitment of SRC co-activators. Consistent with the upregulation of expression of the anti-apoptotic molecule Bcl-x L by RORγt to enhance thymocyte survival 5, 7 , retroviral expression of Bcl-x L (with GFP, as above) partially restored the differentiation of DP thymocytes from Rorγt −/− thymocytes ( Fig. 1f) . However, that retrovirally expressed Bcl-x L was unable to restore the T H 17 differentiation of Rorγt −/− T cells ( Fig. 1g) , which indicated that distinct mechanisms were involved in RORγt-regulated T H 17 differentiation and thymocyte development. 
RORgt M affects T H 17 differentiation but not T cell development
As substitutions that affected the DNA-binding activity of RORγt and the AF2 motif of the ligand-binding domain interfered with both thymocyte development and T H 17 differentiation, we extended the search for structural RORγt elements required differentially for these functions by introducing substitutions in the RORγt hinge domain. By replacing consecutive stretches of five amino acids to alanine residues (alanine scanning), we created 33 mutants that covered the hinge region (amino acids 76-240; Fig. 2a ). We assessed Rorγt −/− DN thymocytes and peripheral Rorγt −/− CD4 + T cells transduced with retrovirus expressing RORγt-GFP or 'alanine-mutant' RORγt for restoration of thymocyte development and T H 17 differentiation in vitro, as described above. 20 of 33 mutants, including a mutant with all alanine residues at positions 176-180 (176-180A) and the mutant 191-195A ( Supplementary Fig. 1g ), restored both thymocyte development and T H 17 differentiation. Seven mutants, including 76-80A ( Fig. 2b) and 181-185A ( Supplementary Fig. 1g ), mark-edly impaired both thymocyte development and T H 17 differentiation. These mutant residues were scattered across the entire hinge domain ( Fig. 2c) , which indicated that functionally important motifs of RORγt for both functions were not clustered together. Six mutants, including 91-95A ( Fig. 2b) and 151-155A ( Supplementary Fig. 1g ), 'preferentially' impaired T H 17 differentiation with limited effects on thymocyte development ( Fig. 2c) , indicative of a selective requirement for those two regions (positions 91-105 and 151-165) for T H 17 differentiation. Mutants with alanine replacement at positions 151-165 maintained more than 50% of the T H 17 differentiation, while the mutant 91-95A maintained most of the thymocyte development but was unable to support T H 17 differentiation ( Fig.  2c) . When presented as the ratio of the frequency of restored thymocyte development to the frequency of restored T H 17 differentiation, mutant 91-95A showed the greatest difference between its ability to support thymocyte development and its inability to support T H 17 differentiation ( Fig. 2c) . 
A r t i c l e s
We further defined which amino acids in the mutant 91-95A were critical for distinguishing between the two RORγt-regulated functions. The amino acid sequence from position 91 to position 95 is Asp-Ser-Leu-His-Ala, and our alanine scan did not change that final alanine. To investigate the requirement for the first four amino acids, we created two three-alanine mutants covering these four amino acids: 91-93A and 92-94A. Similar to mutant 91-95A, both mutant 91-93A and mutant 92-94A supported thymocyte development ( Fig. 2d) , but neither supported T H 17 differentiation ( Fig. 2d) , when retrovirally expressed in Rorγt −/− T cells. Additionally, an S92A-L93A mutant restored the thymocyte development ( Fig. 2e) but not the T H 17 differentiation ( Fig. 2e) of Rorγt −/− T cells. The single mutant S92A preserved both functions, whereas the mutant L93A significantly impaired both thymocyte development and T H 17 differentiation ( Fig. 2e) .
Immunoblot analysis confirmed that all mutants were expressed at a level equivalent to that of wild-type RORγt (Supplementary Fig. 2h ). S92A-L93A was the minimum substitution sufficient to distinctively regulate RORγt-dependent thymocyte development and T H 17 differentiation ( Fig. 2f) Fig. 2a,b) . We found similar expression patterns for Rorγt −/− T cells reconstituted with EV-GFP and those reconstituted with RORγt M -GFP that were different from those of Rorγt −/− T cells reconstituted with RORγt-GFP, an observation confirmed by hierarchical clustering analysis (Fig. 3a) .
Many T H 17 cell signature genes, including Il17a, Il17f, Il23r, Il1r, Ccr6, IL-17re and Il22, were downregulated in EV-GFP + Rorγt −/− T cells relative to their expression in RORγt-GFP + Rorγt −/− T cells (Fig. 3b) , which confirmed the defective T H 17 differentiation. Those T H 17 cell signature genes were also downregulated in RORγt M -GFP + Rorγt −/− T cells relative to their expression in RORγt-GFP + Rorγt −/− T cells (Fig. 3b) .
ChIP-seq analysis identified 21,917 RORγt DNA-binding peaks within loci such as Il17 and Il23r (Fig. 3c) , as well as Il1r, Il17re, Rorc and Ccr6 (Supplementary Fig. 2c) , which encode products known to be critical for T H 17 differentiation. Among the 3,931 RORγt M DNA-binding peaks identified in RORγt M -GFP + cells, almost all (3,886) overlapped the RORγt DNA-binding peaks ( Fig. 3c and Supplementary Fig. 2c ). However, RORγt M lost or showed significantly smaller DNA-binding peaks within loci encoding products known to be critical for T H 17 differentiation ( Fig. 3c and Supplementary Fig. 2c ), which correlated with the diminished expression of these loci (Fig. 3b) . There was much less binding of RORγt M than RORγt to Il17 and Il23r loci, as confirmed by individual ChIP assays (Fig. 3d) . Therefore, RORγt M selectively lost DNA-binding sites and the ability to activate genes encoding products required for T H 17 differentiation.
RORgt M supports thymocyte development in vivo
To investigate the in vivo function of RORγt M , we generated a strain of mouse expressing the mutations encoding the S92A and L93A substitutions of RORγt from the endogenous Rorγt locus (Rorγt M/M mice) ( Supplementary Fig. 3a) . A neomycin-encoding gene used for selection was also deleted by the Flp recombinase ( Supplementary Fig. 3b ), so interference with gene expression was avoided. RORγt M expression was indicated by the detection of mutations encoding S92A-L93A by sequence analysis of Rorγt mRNA (Supplementary Fig. 3c ).
We first assessed T cell development in the Rorγt M/M mice. Intracellular staining of RORγt showed equivalent expression of RORγt M and RORγt in the CD4 + CD8 + DP cells of Rorγt M/M mice and those of wild-type mice, respectively (Supplementary Fig. 4a) , suggestive of appropriate RORγt M expression during T cell development. Rorγt −/− mice had much lower thymic cellularity than that of wild-type mice (Fig. 4a) , due to accelerated spontaneous apoptosis (Fig. 4b) , while the thymic cellularity of Rorγt M/M mice and A r t i c l e s the survival of Rorγt M/M thymocytes were almost equivalent to those of their wild-type counterparts (Fig. 4a,b) . On the basis of their expression of the surface markers CD44 and CD25, DN thymocyte development in Rorγt −/− mice and Rorγt M/M mice was similar to that of wild-type mice 5 (Supplementary Fig. 4b) . The frequency and absolute number of CD4 + single-positive cells and CD4 + CD8 + DP cells was lower in Rorγt −/− thymus than in wild-type thymus, while Rorγt M/M mice had a frequency and number of such cells similar to that detected in wild-type mice ( Fig. 4c and Supplementary Fig. 4c) . Moreover, while CD8 + thymocytes in Rorγt −/− mice were mostly immature CD24 hi TCR lo cells, CD8 + cells in Rorγt M/M thymus were mostly mature CD24 lo TCR hi cells, similar to that of wild-type mice (Fig. 4d) .
In contrast to the enlarged cell size (as assessed by forward scatter) and markedly greater number of cells entering DNA synthesis (S phase of the cell cycle; indicated by cells with >2N DNA) of thymocytes in Rorγt −/− mice relative to that of wild-type mice, Rorγt M/M thymocytes had the same cell size and frequency of cells in S phase that wild-type mice had (Fig. 4e,f) . In addition, RNA-seq analysis indicated that the most prominent apoptotic molecule upregulated in wild-type thymocytes relative to its expression in Rorγt −/− thymocytes was Bcl-x L (encoded by Bcl2l1) (Fig. 4g) . Genes encoding many cellcycle regulators, including cyclins and cell-division-cycle proteins, displayed a change in expression of more than twofold in Rorγt −/− thymocytes relative to their expression in wild-type thymocytes (Fig. 4g) , consistent with the survival and cell-cycle changes observed for Rorγt −/− thymocytes. Changes in the expression of genes encoding Bcl-x L and cell-cycle molecules were significantly less pronounced in Rorγt M/M thymocytes relative to that in wild-type thymocytes than in Ror�t Fig. 5d ), among cells that infiltrated the CNS of host mice as in a (key) in which EAE was induced, assessed by flow cytometry at the peak of disease. (c) qPCR analysis of cytokine-encoding Il17a mRNA (left), Ifng mRNA (middle) and Csf2 mRNA (right) in lymphocytes that infiltrated the CNS of host mice as in a (key) in which EAE was induced (results presented as in Fig. 5e ). Rorγt −/− thymocytes relative to that in wild-type thymocytes (Fig. 4g) , which suggested that Rorγt M/M thymocytes were phenotypically equivalent to wild-type thymocytes but not to Rorγt −/− thymocytes. Thus, RORγt M functioned largely in a way similar to endogenous RORγt in supporting thymocyte development in vivo.
Rorgt M/M mice have defective T H 17 differentiation
The distribution of naive and memory T cells in Rorγt M/M mice was similar to that observed in wild-type mice (Supplementary Fig. 5a,b) .
To determine the function of RORγt M in T H 17 cells, we differentiated naive splenic T cells from wild-type, Rorγt M/M and Rorγt −/− mice under T H 1, T H 17, T H 2 or regulatory T cell conditions. In contrast to wild-type T cells, and similar to Rorγt −/− T cells, Rorγt M/M T cells failed to differentiate into IL-17-producing cells, while there were no obvious differences in the ability of Rorγt M/M T cells to differentiate into T H 1 cells (Fig. 5a) , T H 2 cells (Supplementary Fig. 5c ) or regulatory T cells (Supplementary Fig. 5d ), relative to the corresponding differentiation of wild-type cells, suggestive of a selective defect in T H 17 differentiation. In wild-type T H 17 cells differentiated in vitro, RORγt M expression was equivalent to that of RORγt (Fig. 5b) , which suggested that the defective T H 17 differentiation was not due to lack of RORγt M expression. The development of EAE was attenuated in both Rorγt −/− mice and Rorγt M/M mice, relative to that of wild-type mice (Fig. 5c) , with recovery of considerably fewer CD45 + lymphocytes, including Ly6G + neutrophils, CD3 + T cells, CD19 + B cells and CD11b + monocytes, that had infiltrated the central nervous system (CNS) of Rorγt −/− and Rorγt M/M mice than from the CNS of wild-type mice ( Fig. 5d and Supplementary Fig. 6a) , indicative of diminished inflammation. Analysis of the lymphocytes that had infiltrated the CNS indicated lower expression of Il17a mRNA (which encodes IL-17A), Ifng mRNA (which encodes the cytokine IFN-γ) and Csf2 mRNA (which encodes the cytokine GM-CSF) in such cells from Rorγt M/M mice and Rorγt −/− mice than in such cells from wildtype mice (Fig. 5e) .
To further evaluate this, we adoptively transferred naive wildtype, Rorγt −/− or Rorγt M/M CD4 + T cells into Rag1 −/− mice (which have a congenital deficiency in mature B cells and T cells), followed by the induction of EAE in the host mice. The EAE induced in Rag1 −/− mice reconstituted with Rorγt −/− or Rorγt M/M CD4 + T cells was greatly attenuated relative to that of Rag1 −/− mice reconstituted with wild-type CD4 + T cells (Fig. 6a) , with less infiltration of lymphocytes, including Ly6G + neutrophils, CD4 + T cells and CD11b + monocytes, into the CNS of Rag1 −/− mice reconstituted with Rorγt −/− or Rorγt M/M CD4 + T cells than into the CNS of Rag1 −/− mice reconstituted with wild-type CD4 + T cells ( Fig. 6b  and Supplementary Fig. 6b ). There was also lower expression of Il17a, Ifng and Csf2 mRNA in those infiltrating cells in Rag1 −/− mice reconstituted with Rorγt −/− or Rorγt M/M CD4 + T cells than in those reconstituted with wild-type CD4 + T cells (Fig. 6c,d) . The expression of Il17a mRNA was reduced the most, consistent with the greater reduction in the frequency (Fig. 6e ) and absolute number (Fig. 6f) of IL-17 + IFN-γ + and IL-17 + GM-CSF + T cells, which are believed to be pathogenic for EAE 3, 4, 23 , than of IFN-γ + T cells and GM-CSF + T cells. In contrast, the overall frequency of IFN-γ + cells and GM-CSF + cells in Rag1 −/− mice reconstituted with Rorγt −/− or Rorγt M/M cells was not obviously changed relative to that of Rag1 −/− mice reconstituted with wild-type cells (Fig. 6e,f) , which demonstrated a selective defect in the differentiation of T H 17 cells. Among CD4 + T cells from the draining lymph nodes and, to a lesser extent, among CD4 + T cells from the spleen, the abundance of IL-17 + cells, but not that of IFN-γ + cells, was lower in Rag1 −/− mice reconstituted with Rorγt −/− or Rorγt M/M CD4 + T cells than in those reconstituted with wild-type cells. (Supplementary Fig. 6c ). We did not observe a difference in the expression of Foxp3 (which encodes the transcription factor Foxp3) in T cells from wild-type mice in which EAE was induced relative to its expression in T cells from their Rorγt M/M counterparts (Supplementary Fig. 6d ).
Next we assessed the expression of genes encoding representative pathogenic or nonpathogenic molecules in wild-type and Rorγt M/M CD4 + T cells differentiated with either TGF-β plus IL-6 (the nonpathogenic T H 17-priming condition) or with TGF-β plus IL-6 plus IL-23 (the pathogenic T H 17-priming condition), calculated as the ratio of expression in wild-type cells to that in Rorγt M/M cells. The expression of genes encoding nonpathogenic molecules did not generally change more than twofold in wild-type T cells relative to that in Rorγt M/M T cells in either priming condition (Fig. 6g) . However, many genes encoding pathogenic molecules had higher expression in wild-type T cells than in Rorγt M/M T cells under the nonpathogenic priming condition (Fig. 6g) . Some genes encoding pathogenic molecules had lower expression in wild-type T cells than in Rorγt M/M T cells, but the difference was usually less than twofold (Fig. 6g) . All the genes encoding pathogenic molecules that we detected had higher expression in wild-type T cells than in Rorγt M/M T cells in the presence of IL-23 (Fig. 6g) . In the analysis such gene expression in T cells obtained from mice in which EAE was induced, many genes encoding pathogenic molecules had higher expression in wild-type T cells than in Rorγt M/M T cells, whereas some had lower expression in in wildtype T cells than in Rorγt M/M T cells, but the difference was usually less than twofold (Fig. 6h) . Therefore, Rorγt M/M T cells showed lower pathogenic potential, with a loss of function in supporting T H 17 differentiation and the induction of EAE in vivo.
Rorgt M/M mice develop lymph nodes but not Peyer's patches
Because Rorγt −/− mice typically lack all lymph nodes 5 , we assessed lymph-node development in Rorγt M/M mice. In contrast to Rorγt −/− mice, Rorγt M/M mice had almost all of the lymph nodes assessed, including aortic lymph nodes and gut-associated mesenteric lymph nodes (Fig. 7a,b) . The inguinal lymph nodes of Rorγt M/M mice developed but were smaller than those found in wild-type mice, as reflected by their reduced cellularity (Fig. 7b) . Consistent with that, the number of group 3 innate lymphoid cells (ILC3s), which show enrichment for lymphoid-tissue-inducer cells, in mesenteric lymph nodes of Rorγt M/M mice was comparable to that in their wildtype counterparts (Supplementary Fig. 6e,f) . However, Rorγt M/M mice failed to develop Peyer's patches, similar to Rorγt −/− mice (Fig. 7a,b) , consistent with evidence indicating that development A r t i c l e s of Peyer's patches and that of other peripheral lymph nodes depend on different pathways 24, 25 . RORγt M was thus able to support the development of most lymph nodes, except Peyer's patches.
RORγt M interferes with ubiquitination of RORγt at Lys69
To understand how the two-alanine substitution in RORγt M affected its function, we first monitored RORγt M activity using a RORγt-luciferase reporter. RORγt recruits the transcriptional co-activator SRC1 via an AF2 motif within the ligand-binding domain 18, 26 . RORγt M and wild-type RORγt interacted with SRC1 and stimulated RORγt-luciferase reporter activity to a similar degree ( Supplementary Fig. 7a,b) . RORγt is ubiquitinated in T H 17 cells 26 .
Comparison of the RORγt-ubiquitination patterns in cells isolated from wild-type, Rorγt −/− or Rorγt M/M mice indicated that the ubiquitination of RORγt M was lower than that of wild-type RORγt not only in differentiated T H 17 cells but also in thymocytes (Fig. 8a) . We then immunoprecipitated RORγt and RORγt M for mass-spectrometry analysis of ubiquitinated lysine residues. Digestion of ubiquitinated lysine leaves a glycine-glycine isopeptide linked to the lysine, which can be easily detected by mass spectrometry as an increased mass of 114.102 Da (ref. 27) . We detected ubiquitination signals at Lys69 in wild-type RORγt, but not in RORγt M , immunoprecipitated from differentiated T H 17 cells (data not shown). We then monitored the ubiquitination of RORγt in HEK293T human embryonic kidney cells transfected to express wild-type RORγt or RORγt M and hemagglutinin-tagged ubiquitin (HA-ubiquitin), followed by immunoprecipitation of RORγt. There was less ubiquitinated RORγt M than ubiquitinated wild-type RORγt (Fig. 8b) . To specifically evaluate ubiquitination of Lys69, we generated a mutant RORγt in which all 23 lysine residues, except Lys69, were replaced with arginine (RORγt-K69), so that only Lys69 could be ubiquitinated. RORγt-K69 was polyubiquitinated at Lys69 in HEK293T cells (Fig. 8b) , while introduction of the L92A-S93A substitutions to RORγt-K69 (RORγt M -K69) markedly impaired the ubiquitination of Lys69 (Fig. 8b) ; this confirmed that those two amino-acid substitutions in RORγt M interfered with the ubiquitination of Lys69. The alanine-scanning mutant 91-95A had greatly impaired ubiquitination at Lys69, but the three alanine-scanning mutants 151-155A, 156-160A and 161-165A did not (Supplementary Fig. 7c ). We next determined whether the polyubiquitin chains on RORγt-K69 were K63 linked or K48 linked 28 . Replacement of all seven lysine residues of ubiquitin within HA-ubiquitin with arginine or replacement of only the lysine at position 63 with arginine (to assess K63-linked ubiquitination) prevented the ubiquitination of RORγt at Lys69, whereas replacement of all seven lysine residues of ubiquitin within HA-ubiquitin except the lysine at position 63 with arginine did not affect that ubiquitination (Fig. 8c) . This suggested the formation of K63-linked polyubiquitin chains at Lys69 of RORγt. In contrast, replacement of the lysine at position 48 in the ubiquitin of HA-ubiquitin with arginine (to assess K48-linked ubiquitination), did not affect the ubiquitination of RORγt at Lys69, whereas replacement of all seven lysine residues of ubiquitin within HA-ubiquitin except the lysine at position 48 with arginine prevented the ubiquitination of RORγt at Lys69 (Fig. 8c) , which indicated that the polyubiquitin chains at Lys69 for RORγt were not K48 linked. An important function of ubiquitination is to regulate protein degradation 28 , and ubiquitination is reported to regulate the stability of RORγt [29] [30] [31] [32] . However, the expression of RORγt M was not different from that of wild-type RORγt at various times after the treatment of differentiated T H 17 cells with the protein-synthesis inhibitor cycloheximide (Supplementary Fig. 7d,e) , which indicated that the degradation rate of RORγt M was the same as that of wild-type RORγt and correlated with the observation that the different levels of ubiquitination in RORγt M and wild-type RORγt were not due to the K48-linked polyubiquitin chains that target proteins for degradation 28 .
To determine the role of the ubiquitination of Lys69 in functions regulated by RORγt, we replaced the lysine at position 69 of RORγt K69 with arginine (K69R) to prevent ubiquitination. As a control, we replaced the lysine at position 81 of RORγt with arginine (K81R), as Lys81 of RORγt was not ubiquitinated, as assessed by mass spectrometry (data not shown). K69R interacted with SRC1 and stimulated RORγt-luciferase reporter activity to an extent similar to that achieved with RORγt M and RORγt in HEK293T cells (Supplementary Fig. 7b,f) . In thymocyte-development and T H 17-differentiation assays, retroviral expression of K69R restored 90% of the development of Rorγt −/− thymocytes, similar to that supported by wild-type RORγt and K81R, and slightly greater than the thymocyte development supported by RORγt M (Fig. 8d,e) ; this suggested that the ubiquitination of Lys69 was not essential for RORγt-mediated thymocyte development. In contrast, K69R restored only about 45% of the T H 17 differentiation of Rorγt −/− T cells, which was much less than that supported by wild-type RORγt or K81R (Fig. 8d,e ). That correlated with lower expression of T H 17 cell signature genes, including Il17a, IL17f and Ccl20 (Fig. 8f) , as well as less binding of RORγt to the promoter of the gene encoding IL-17 ( Fig. 8g) , in Rorγt −/− T cells transduced to express K69R than in those transduced to express wild-type RORγt or K81R. Therefore, the ubiquitination of Lys69, although dispensable for thymocyte development, was needed to promote T H 17 differentiation. However, because K69R was more potent than RORγt M in supporting T H 17 differentiation, lack of the ubiquitination of Lys69 was only partially responsible for the failed T H 17 differentiation observed in the Rorγt M/M T cells.
DISCUSSION
In this study, we identified a two-amino-acid substitution in the hinge region of RORγt that allowed normal thymocyte development but not T H 17 differentiation. While Rorγt −/− mice exhibit multiple defects, including thymocyte and ILC3 development, lymph-node genesis and T H 17 differentiation, Rorγt M/M mice exhibited a specific defect in T H 17 differentiation while maintaining thymocyte development. Rorγt M/M mice also developed ILC3s, but these were defective in their production of IL-17 (data not shown). Therefore, RORγt M preserved its function in 'instructing' T cell and ILC3 development but selectively disrupted the IL-17 production function of mature cells. We further demonstrated that the two-amino-acid substitution impaired the ubiquitination of RORγt at Lys69 that was selectively required for T H 17 differentiation, not for thymocyte development.
Rorγt −/− mice have a high incidence of thymic lymphoma, probably due to dysregulated thymocyte development, including cell-cycle and apoptosis changes 6 . Because thymocyte development in Rorγt M/M mice was largely normal, lymphoma development seemed unlikely. Indeed, we did not detected lymphoma among more than 160 Rorγt M/M mice analyzed, including 25 mice at 24 weeks of age, 8 mice 37-39 weeks of age and 7 mice older than 39 weeks of age (data not shown), while more than 50% of Rorγt −/− mice die of lymphoma before 39 weeks of age 6 . These results support the idea that the lymphoma in Rorγt −/− mice results from abnormal thymocyte development.
The RORγt S92A-L93A substitutions were the minimal alterations in the hinge region that selectively disrupted the function of RORγt in T H 17 differentiation without affecting thymocyte development. Although Ser92 is a potential phosphorylation site, the mutant S92A, which cannot be phosphorylated, did not affect the function of RORγt. In contrast, the mutant L93A affected both RORγt-mediated thymocyte development and RORγt-mediated T H 17 differentiation. Analysis of RORγt with the two-amino-acid substitution S92A-L93A (RORγt M ) was able to maximally separate the function of RORγt in thymocytes and its function in T H 17 differentiation. The alterations in RORγt M did not affect its activity, recruitment of the co-activator SRC1 or stimulation of a reporter, which suggested that the two-amino-acid substitution did not affect overall RORγt function. However, RORγt M had impaired ubiquitination at Lys69, which was required for T H 17 differentiation but not thymocyte development. Therefore, post-translational ubiquitination has an important role in distinguishing the function of RORγt in T H 17 differentiation from its function in thymocyte development. Although ubiquitination is known to regulate protein degradation 28 , the alterations in K69R and RORγt M did not affect the amount of RORγt protein and thus did not support the function of the ubiquitination of Lys69 in the regulation of RORγt's stability. That conclusion was further confirmed by the K63-linked but not K48-linked ubiquitination of RORγt at Lys69. The fact that Lys69 is in the DNA-binding domain and the finding that the K69R substitution impaired the binding of RORγt to the locus encoding IL-17 supported the proposal that alterations in RORγt M affected its DNA-binding activity selectively in T H 17 cells via interference with the ubiquitination of Lys69. That possibility was strengthened by our global analysis indicating that RORγt M failed to bind to or stimulate genes encoding molecules critical for T H 17 differentiation, whereas it did not significantly affect the expression of genes encoding molecules involved in cell survival and the cell cycle that are critical for thymocyte development. It still remains to be determined how ubiquitination of Lys69 is selectively required for T H 17 differentiation but not for thymocyte development. One of the possibilities is that ubiquitination of Lys69 induces the recruitment of a co-factor to RORγt specifically in T H 17 cells, which could be determined by comparison of RORγt-associated proteins in T H 17 cells with those in thymocytes. In addition, the enzymes responsible for modifying Lys69 of RORγt remain unknown. The identification of such enzymes would facilitate the development of drugs that specifically target RORγt-mediated pathological autoimmune T H 17 responses without interfering with thymocyte development or lymph-node genesis.
Mutations in the gene encoding RORγt reported in humans result in susceptibility to fungal and mycobacterial infection 33 . However, those mutations alter either the DNA-binding domain or the ligand-binding domain. Humans bearing mutations in the gene encoding RORγt also have defects in lymph-node genesis and thymocyte apoptosis 33 , which is consistent with the phenotypes observed in Rorγt −/− mice and suggests function conservation between human RORγt and mouse RORγt. It will be important to investigate if modifications of the Ser92-Leu93 motif identified in mice also distinguishes the function of RORγt in thymocyte development and its function in T H 17 differentiation in humans.
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